Table 1. In-depth Analysis of Serious Complications of Filler Injections.
| Location and Type of Filler | No. (%)a | |||
|---|---|---|---|---|
| Arterial Only | Blindness | Necrosis | Total No. of Injections | |
| Location | ||||
| Lip | 81 (15.4) | 0 | 35 (6.7) | 525 |
| Nasolabial fold | 63 (14.7) | 0 | 36 (8.4) | 428 |
| Cheek | 51 (6.8) | 0 | 3.2 (24) | 751 |
| Marionette line | 13 (6.9) | 0 | 7 (3.7) | 189 |
| Periorbital | 0 | 4 (2.9) | 3 (2.2) | 137 |
| Forehead | 12 (13.3) | 3 (3.3) | 16 (17.7) | 90 |
| Dorsal aspect of nose | 0 | 1 (16.7) | 0 | 6 |
| Fillerb | ||||
| Hyaluronic acid | 151 (9.4) | 7 (0.4) | 136 (8.5) | 1605 |
| Sculptra | 4 (8.5) | 0 | 2 (4.3) | 47 |
| Radiesse | 27 (28.1) | 1.0 (1.0) | 29 (30.2) | 96 |
a
Percentages indicate the fraction in that specific location or for that specific filler only. P < .001 for all comparisons.
b
Sculptra (poly-L-lactic acid), Sanofi; Radiesse (calcium hydroxylapatite), Merz Pharmaceuticals).